Kersten, Marie José, Martin Dreyling, Kim M. Linton, Dana Chitu, Gerben J.C. Zwezerijnen, Sanne H. Tonino, Marcel Kap, Roberto Liu, Christel van Hooije, Martine E.D. Chamuleau, Hein P.J. Visser, Eva de Jongh, Erik A.F. Marijt, Maria B.L. Leys, Yavuz M. Bilgin, Jan Dürig, Pamela McKay, Tjeerd Snijders, Andrew Pettitt, Monique C. Minnema, Gabriele Prange-Krex, Marloes L.H. Cuijpers, Lara H. Bohmer, Lidwine W. Tick, Axel Florschutz, Matthijs Silbermann, Rob Fijnheer, Aart Beeker, Nelleke Tolboom, Cristina Mitea, Anne I.J. Arens, Sanne E. Wiegers, Martijn W. Heymans, Wolfram Klapper, Sarah E. Coupland, Daphne de Jong, Jeanette K. Doorduijn, and Josée M. Zijlstra. 2020. “Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine for relapsed/refractory Follicular Lymphoma: Primary and Final Analysis of the Randomized Phase II HOVON110/ReBeL Study”. Haematologica, September. Pavia, Italy. https://doi.org/10.3324/haematol.2025.300152.